“…Both C4a and C3a levels are predictive of the responses of esophageal cancer patients to chemoradiation (Maher et al, 2011). In more obviously inflammatory disorders, C3a (and to a lesser extent C4a) have been shown to be potentially useful markers in dermatomyositis (Campo et al, 2007), aneurysmal subarachnoid hemorrhage (Mack et al, 2007), acute Lyme disease in tick-bite patients (Shoemaker et al, 2008;Stricker et al, 2009) (Fassbender et al, 2009), adverse pregnancy outcomes (Lynch et al, 2011), chronic obstructive pulmonary disease (Marc et al, 2004;Zhang et al, 2011), cryptogenic and large-vessel disease subtypes of stroke (Stokowska et al, 2011), heart failure (Gombos et al, 2012), cerebral arteriovenous malformations (Haque et al, 2011), asthma (Joks et al, 2008), gestational diabetes mellitus (Lappas, 2011), SLE (Wild et al, 1990), acute relapses in multiple sclerosis (Ingram et al, 2010), IgA nephropathy/Henoch-Schonlein nephritis (Abou-Ragheb et al, 1992) and impaired renal function (Abou-Ragheb et al, 1991), atopic dermatitis (Sergeev Iu et al, 1989), psoriasis (Takematsu et al, 1986) and psoriatic arthritis (Muto et al, 1991), idiopathic pulmonary arterial hypertension (Abdul-Salam et al, 2006), postexercise malaise in myalgic encephalomyelitis/chronic fatigue syndrome (Nijs et al, 2010), AIDS-associated retinitis , and grafted corneas . In addition, C4a and C5a levels decrease after liver resection whereas C3a levels increase (Strey et al, 2009); and C3a and C4a are elevated in liver transplant recipients (Pfeifer et al, 2000).…”